Table 2 Distribution of resistance-associated mutations among 15 patients with viral loads > 1000 copies/ml, at 3–12 months after ART initiation
Patient | Sex | HIV type | HIV-1 subtype | Initial CD4 | Baseline viral load | ART | Time from ART to re-sistance test (days) | NNRTI resistance | NRTI resistance | PI resistance | Predicted resistance to the following agents |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | HIV-1 | CRF02_AG | 32 | 132,355 | AZT + 3TC + EFV | 319 | K103N | M184M/V | None | EFV/NVP, 3TC/FTC. |
2 | F | HIV-1 | CRF02_AG | 33 | 61,978 | AZT + 3TC + NVP | 362 | K103N Y188CY | None | L10I/V/F/R/Y | EFV/NVP. Resistance to most PIs when present with other mutations. |
3 | F | HIV-1/2 | CRF02_AG | 279 | 11,348 | AZT + 3TC + IND/r | 177 | None | None | None | None |
4 | M | HIV-1/2 | CRF02_AG | 50 | 360,158 | AZT + 3TC + IND/r | 161 | K101E | None | K20R/M/I/T/V | Intermediate NVP. Low-level ETR, RPV, EFV. Potentially low-level NFV resistance. |
5 | M | HIV-1 | CRF02_AG | 207 | 55,650 | AZT + 3TC + EFV | 114 | None | None | None | None |
6 | M | HIV-1 | CRF02_AG | 46 | 360,978 | AZT + 3TC + EFV | 203 | K103N K101E/K | M184MV | None | High-level 3TC/FTC. |
Low-level ddI, ABC. | |||||||||||
High-level EFV/NVP. | |||||||||||
Low-level EFV, ETR, RPV. | |||||||||||
7 | F | HIV-1 | A | 40 | 216,270 | AZT + 3TC + NVP | 126 | K103N | M184V | L10I/V/F/R/Y | High-level 3TC/FTC. |
High-level EFV/NVP. | |||||||||||
Resistance to most PIs when present with other mutations. | |||||||||||
8 | F | HIV-1/2 | CRF02_AG | 258 | 46,763 | AZT + 3TC + IND/r | 189 | None | None | None | None. |
9 | M | HIV-1 | CRF02_AG | 159 | 869,295 | AZT + 3TC + EFV | 281 | None | None | None | None. |
10 | F | HIV-1 | CRF02_AG | 94 | 485,983 | AZT + 3TC + NVP | 98 | V106A Y188C | None | K20R/M/I/T/V | High-level NVP, low-level EFV. Potentially low-level NFV resistance. |
11 | F | HIV-1 | CRF02_AG | 149 | 212,560 | AZT + 3TC + NVP | 344 | K103N | None | None | High-level EFV/NVP. |
12 | M | HIV-1 | CRF02_AG | 107 | 34,698 | AZT + 3TC + EFV | 193 | None | M184MV M184 V/I | K20R/M/I/T/V | High-level 3TC/FTC. |
Low-level ABC, ddI. Potentially low-level NFV resistance. | |||||||||||
13 | F | HIV-1 | A | 71 | 25,000,000 | D4T + 3TC + NVP | 98 | Y181C | T69D | L10I/V/R/Y | Low-level ddI. |
High-level NVP. | |||||||||||
Resistance to most PIs when present with other mutations. | |||||||||||
14 | M | HIV-1 | CRF02_AG | 147 | 185 | AZT + 3TC + NVP | 91 | None | None | L33F | Contributed resistance to FPV/r, DRV/r, LPV/r, ATV/r, TPV/r. |
15 | M | HIV-1 | CRF02_AG | 252 | Un-detectable | AZT + 3TC + EFV | 185 | None | None | None | None. |